Here, we retrospectively analyzed 579 metastatic breast cancer patients from our next-generation sequencing (NGS) database with comprehensive clinicopathological features, including HER2 statuses in both primary and metastatic tumors, metastasis sites and clinical outcomes. This evidence concerns the gene ERBB2 and breast carcinoma.